The shares modified arms via block offers on the Nationwide Inventory Alternate, with the transaction executed at ₹1,730 a share. The deal concerned about 44.9 lakh shares, with personal fairness investor ChrysCapital, via its affiliate Sepia Investments, and Anchor Companions promoting a part of their holdings. ADIA purchased 39,130 shares, whereas different patrons included Aberdeen Group, Manufacturing facility Mutual Insurance coverage Firm, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, Ashoka WhiteOak and different funds.
Corona Cures’ shares rose practically 3 per cent after the transaction, buying and selling round ₹1,840 on the NSE, because the market learn the entry of enormous home and abroad establishments as a vote of confidence within the firm’s branded formulations enterprise. The block deal valued the stake at a premium to the corporate’s public challenge worth band of ₹1,008-₹1,062 a share in December 2025, underlining the sturdy post-listing efficiency of the inventory.
Sepia Investments offered 43.28 lakh shares, equal to about 7.07 per cent of Corona Cures’ fairness, for round ₹748.9 crore. Anchor Companions offloaded 1.61 lakh shares, or 0.26 per cent, for about ₹28 crore. Sepia’s stake fell to 12.69 per cent from 19.76 per cent after the sale, whereas the broader possession base introduced extra institutional depth to the corporate’s shareholder register.
The transaction can also be a partial exit for early monetary traders who backed Corona Cures earlier than its public itemizing. For patrons, the attraction lies in a home formulations franchise with established manufacturers throughout girls’s healthcare, cardio-diabeto, ache administration, urology and different therapeutic classes. The corporate has positioned itself in segments with increased repeat prescription potential and comparatively stronger pricing resilience than low-margin commodity generics.
Corona Cures reported income progress of about 17 per cent within the monetary yr ended March 2026, whereas revenue after tax rose about 33 per cent. Its full-year income crossed ₹1,400 crore, supported by progress in continual and sub-chronic therapies, brand-led advertising and marketing and wider distribution. The corporate’s earlier public provide was solely a proposal on the market, that means the proceeds went to current shareholders somewhat than to the corporate.
The drugmaker was ranked among the many prime 30 pharmaceutical corporations within the home pharmaceutical market by gross sales earlier than its itemizing. Girls’s healthcare is one in all its strongest verticals, adopted by cardio-diabeto, ache administration and urology. Its model portfolio consists of merchandise focused at specialist docs, a technique that has helped it command increased prescription visibility in chosen therapies.
The stake buy comes at a time when pharmaceutical corporations with sturdy home franchises are drawing investor curiosity. Firms targeted on branded formulations have benefited from rising healthcare consumption, deeper insurance coverage penetration, increased prognosis charges for continual circumstances and stronger prescription volumes in city and semi-urban markets. The home pharmaceutical market has additionally been much less uncovered to a number of the pricing and regulatory volatility confronted by export-heavy generic drugmakers.
ADIA’s participation suits a broader sample of Gulf sovereign capital looking for publicity to healthcare, prescribed drugs, monetary companies, infrastructure and shopper platforms throughout progress markets. The Abu Dhabi fund has constructed a diversified international portfolio and has been lively in personal fairness, listed equities, actual property and options. Its entry into Corona Cures, although modest in proportion phrases, provides to institutional curiosity in healthcare companies with predictable money flows and long-term demand visibility.
For Corona Cures, the deal improves public float high quality and will assist market liquidity. Better institutional possession may carry nearer scrutiny of margins, product focus, compliance, capital allocation and future acquisition technique. The corporate’s subsequent section might be measured in opposition to its potential to take care of progress whereas defending profitability in a market the place promotional bills, field-force productiveness and physician engagement stay vital.
The transaction additionally highlights how block offers have grow to be an essential route for personal fairness funds to monetise stakes after listings. Reasonably than ready for gradual market gross sales, giant shareholders can exit or pare publicity via negotiated alternate transactions that enable institutional patrons to amass sizeable positions in a single buying and selling window. Such offers can cut back overhang when executed cleanly, although additionally they put concentrate on valuation sustainability after the preliminary market response.
